Showing results (351-360 of 531) with videos related to

Sort By:
Pageof 54
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
The American Journal of Cardiology|March 23, 2000
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisM C Thel, R M Califf, B E Tardiff, et al.
Diabetes, Obesity & Metabolism|August 31, 2019
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trialJeroen V Koomen, Hiddo J L Heerspink, Ilse C Schrieks, et al.
European Heart Journal|October 18, 2003
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trialS Savonitto, P W Armstrong, A M Lincoff, et al.
JAMA Cardiology|July 9, 2020
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialRishi Puri, Steven E Nissen, Benoit J Arsenault, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2003
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis modelKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
Thrombosis and Haemostasis|August 3, 2002
Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusionKai Wang, Xiaorong Zhou, Zhongmin Zhou, et al.
The American Journal of Medicine|July 31, 2017
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION TrialDaniel H Solomon, M Elaine Husni, Peter A Libby, et al.
Journal of the American Heart Association|November 23, 2019
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE TrialAnirudh Kumar, Divyang R Patel, Danielle M Brennan, et al.
American Heart Journal|September 29, 2014
Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary interventionAkshay Bagai, Phillip J Schulte, Christopher B Granger, et al.
Pageof 54